MediSapiens received funding for groundbreaking cancer medicine software
MediSapiens has received USD 1 million for the world’s first personalized cancer medicine software.
MediSapiens, world’s first software company for personalized cancer medicine in oncology clinics and drug development, completed USD 1 million round investment from ETFIII advised by Eqvitec Partners, Veraventure, VTT Ventures and Lifeline Ventures.
MediSapiens is based on scientific research at the VTT Technical Research Centre of Finland and its collaborators. MediSapiens hosts world’s largest unified gene expression database of human tissues and diseases. This enables scientists to understand the role of human genes in health and disease – to be applied in helping oncologists in choosing optimal treatments and biopharmaceutical companies in developing next generation personalized medicines.
Read more